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a b s t r a c t
South Asians account for around 25% of the global population and are the fastest-growing ethnicity in the US. This
population has an increasing burden of atherosclerotic cardiovascular disease (ASCVD) which is also seen in the
diaspora. Current risk prediction equations underestimate this risk and consider the South Asian ethnicity as a
risk-enhancer among those with borderline-intermediate risk. In this review, we discuss why the South Asian
population is at a higher risk of ASCVD and strategies to mitigate this increased risk.
Published by Elsevier Inc.
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onset <55 years of age among men and <65 years among women,13
premature mortality is deﬁned as death <70 years among both men
and women.14
In the INTERHEART study (see Table 1 for study description), the
mean age of ﬁrst myocardial infarction (MI) was 53 years in South
Asia compared to around 63 years in China and Europe.15 A higher proportion of South Asian patients had their ﬁrst MI <40 years of age (8.9%
vs 2.7% and 2.9% for China and Europe, respectively).15 In the
Bangladesh Risk of Acute Vascular Event (BRAVE) study, the mean age
among patients with MI was 53 ± 10 years (n = 4500), and 46% of
the patients had age ≤ 50 years.16

Introduction
The burden of atherosclerotic cardiovascular disease (CVD;
ASCVD) is rising rapidly in South Asia.1,2 Since 2010, the crude proportion of deaths due to coronary artery disease (CAD) has increased
at an annual rate of 2.1% in South Asia compared to 0.8% globally.3
South Asians have a signiﬁcantly higher proportion of premature
deaths from ASCVD.4
Guidelines recognize that current risk prediction models underestimate the ASCVD risk among South Asians.5 South Asian ancestry is considered a risk enhancer to determine eligibility for statin use among
those with borderline or intermediate 10-year ASCVD risk estimated
by the Pooled Cohort Equations.5 We discuss why the South Asian population is at a higher risk of premature ASCVD, the underlying pathophysiology for this elevated risk, and risk mitigation strategies.

The burden of CVD among South Asians living outside South Asia
A recent study using data from the National Health Interview Survey
2006–2015 in the US suggests that the odds of self-reported premature
ASCVD are 77% higher among Asian Indians compared to Whites in the
US, after adjusting for traditional CVD risk factors.20
Mortality data from the US National Center of Health Statistics from
2003 to 2017 suggest that while the age-standardized mortality rate for
CAD decreased in all Asian subgroups, it remained stagnant for Asian
Indian men (average annual percent change for Asian Indian men compared to overall Asian men −0.9% [95% CI -2.1, 0.4, p = 0.20] compared
to −3.1% [95% CI -3.9, −2.4, p < 0.01]).21 While the rate declined among
all Asian women, the rate of decline was lowest among Asian Indian
women (average annual percent change for Asian Indian women compared to overall Asian women −2.2% [95% CI -3.1, −1.2, p < 0.01] compared to −4.0% [95% CI -4.6, −3.4, p < 0.01]).21 Further, Asian Indian
men and women were the only Asian subgroup population where
there was a trend towards increased age-standardized mortality rate
after 2011.21

Epidemiology
People from Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan,
and Sri Lanka are classiﬁed as South Asian. They constitute around
25% of the world population.6 According to the 5-year estimates of the
American Communities Survey in 2020, around 5.5 million South
Asians live in the United States (US).7,8 Around 81% of South Asians in
the US trace their ancestry to India followed by Pakistan (10%) and
Bangladesh (3%).7
Each South Asian country has a unique culture with signiﬁcant
within-country heterogeneity. A Prospective Urban Rural Epidemiology
(PURE) sub-study reported that in South Asia, the incidence of CVD is
highest in Bangladesh and rural areas.9 Among South Asians enrolled
in the Mediators of Atherosclerosis in South Asians Living in America
(MASALA) cohort in the US, Pakistanis (n = 67) had higher age- and
gender-adjusted odds of dyslipidemia (odds ratio 2.01 with 95% conﬁdence interval [CI] 1.20, 3.39) compared to North Indian participants
(n = 728).10 Any summary measure of CVD risk proﬁle and risk mitigation strategies among South Asians has to be interpreted by considering
this heterogeneity.
To better understand the impact of acquired risk factors and acculturation, the South Asian population can be categorized into 2 groups:
those living in South Asia, and outside South Asia.11,12

Methodological concerns in epidemiological studies among South
Asians living outside South Asia
The majority of the South Asians currently living outside South Asia
are immigrants.22 First-generation immigrants tend to be older and
have a higher CVD risk factor burden.22 But in prospective cohort studies, immigrants, in general, tend to have a lower mortality rate despite
this higher CVD risk factor burden.23 This could be because healthier individuals are more likely to migrate, and migrants may return to their
country of residence when death is imminent (the so-called Salmon
effect).24–26 Any study investigating the mortality rate among the immigrant South Asian population should keep this limitation in context.

The burden of CVD in South Asia
A recent analysis of CVD burden in Asian countries using mainly the
Global Burden of Disease (GBD) 2019 data reported that the proportion
of total deaths due to CVD was 22.7%, 27.4%, and 43.0% in Pakistan, India,
and China, respectively.4 However, a higher proportion of CVD-related
deaths in Pakistan and India were premature (deﬁned as <70 years,
59.3%, 50.6%, and 28.0% in Pakistan, India, and China, respectively).4 It
is important to note that while premature ASCVD is deﬁned as an

CVD risk factors
Among South Asians, there is a premature clustering of dyslipidemia,
diabetes mellitus (DM), and hypertension, which are considered the
2
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Table 1
Description of major studies on CVD epidemiology in South Asians.
Study design
The Effect of Potentially Modiﬁable Risk
Factors Associated with Myocardial
Infarction (INTERHEART)15

Case-Control

Mediators of Atherosclerosis in South Asians
Living in America (MASALA)17

Prospective Cohort

UK Biobank19

Prospective Cohort

15,152 cases of acute MI and 14,820 age- and sex-matched controls from 262 centers in 52
countries between February 1999 and March 2003.
1732 acute MI cases and 2204 controls were recruited from 15 centers in 5 South Asian countries
India: 470 cases, 940 controls; Pakistan: 637 cases, 655 controls; Bangladesh: 228 cases, 238
controls; Sri Lanka: 153 cases, 132 controls; Nepal: 244 cases, 239 controls
10,728 cases and 12,431 controls were enrolled from other countries in Europe, the Middle East,
Africa, Australia, North America, and South America
906 participants with mean age of 55 ± 9 years, 46% female, 84% Asian Indians (≥3 grandparents
born in either India, Pakistan, Bangladesh, Nepal or Sri Lanka) enrolled from 2010 to 2013, baseline
examination same as in Multi-Ethnic Study of Atherosclerosis18
Follow-up for aggregate CVD outcome including CAD (deﬁnite and probable MI, deﬁnite CAD death,
resuscitated cardiac arrest, deﬁnite angina, and probable angina associated with coronary
revascularization), stroke (fatal or nonfatal), and other ASCVD death)
>500,000 individuals between 40 and 69 years of age enrolled between 2006 and 2010 in the
United Kingdom
A subset of 8124 participants self-reported South Asian ancestry, deﬁned as self-identiﬁed Indian,
Pakistani, Bangladeshi, Bhutan, Maldives, Nepal, or Sri Lanka
Primary end point incident ASCVD, deﬁned as hospitalization due to a diagnosis of acute MI,
ischemic stroke, or their acute complications; coronary revascularization procedures (coronary
artery bypass graft surgery or percutaneous angioplasty/stent placement); or death register
indicating MI or ischemic stroke as a cause of death

ASCVD: atherosclerotic cardiovascular disease, CAD: coronary artery disease; MI: myocardial infarction; CVD: cardiovascular disease.

most important CVD risk factors (Fig. 1). Table 2 summarizes ﬁndings
from selected studies comparing CVD risk factors among South Asians
with other races/ethnicities.

DM
Key points
• DM affects South Asians at an earlier age and at a lower body mass
index (BMI) compared to other races/ethnicities.
• DM plays an outsized role in the pathogenesis of ASCVD in South
Asians.

Hypertension
Key points
• There is a high prevalence of hypertension in all South Asian
countries.
• A higher proportion of children and young adults have hypertension
compared to other races/ethnicities.
• The risk of CVD may increase at a higher rate per unit rise in blood
pressure among South Asians compared to other races/ethnicities.

There is an epidemic of DM in South Asia, with a high incidence from
an early age.51 In the UK Biobank Prospective Cohort Study, South
Asians had a higher prevalence of DM compared to Europeans (19.5%
vs. 5.3%, p < 0.001).50 A comparative analysis of South Asians enrolled
in the MASALA (see Table 1 for study details) cohort and other races/
ethnicities in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort
reported a higher age-adjusted prevalence of 23% among South Asians
compared to 6% in non-Hispanic (NH) White, 19% in African
Americans, and 13% in Chinese Americans.52 The higher prevalence, at
a lower age and lower BMI, has been attributed to lower β cell function,
and higher insulin resistance among South Asians.52–54
The US Preventive Services Task Force (USPSTF) recommends
screening for DM in adults aged 35–70 years with a BMI ≥25 kg/m2.55
The USPSTF cautioned that these standard cutoffs for age and BMI may
not apply to Asian Americans.55 South Asians should be screened at an
earlier age and at a lower BMI. In a recent analysis of National Health
and Nutrition Examination Survey (NHANES) data for non-pregnant
adults aged 18–70 years from 2011 to 2018, among those with
normal BMI (18.5–24.9 kg/m2), the prevalence of DM among White
Americans and Asian Americans was 3.5% and 13.0%, respectively.56
There was no data to speciﬁcally assess the equivalent age cut-off
among South Asians in this study. The American Diabetes Association
has a lower BMI threshold of ≥23 kg/m2 for South Asian ancestry
(compared to ≥25 kg/m2 for other races/ethnicities) but screening is
recommended only after the age of 45 years.57
DM may play an outsized role in future ASCVD events among South
Asians. Data from the UK Biobank study suggests that DM has a larger
population attributable fraction for future CVD events among South
Asian compared to European Ancestry, explaining 22% and 7% risk, respectively (p < 0.005).50 This increased attributable risk might be due
to a prolonged asymptomatic stage with less screening, poor control

There is a high prevalence of hypertension in South Asia, both in
rural and urban areas, in adults and children.44–46 A recent analysis of
679,912 Indian adults with a median age of 31 years reported the prevalence of hypertension as around 43% according to the 2017 American
College of Cardiology (ACC)/ American Heart Association (AHA) Hypertension guideline criteria.47 A similar study among 13,519 participants
with a median age of 38 years in Nepal reported a similar prevalence
of 44.2%.48
Exposure to higher blood pressure from an early age might be the
most important risk factor for premature CVD in South Asia.1 A comparative analysis of hypertension prevalence among 5–14-year-old children in Pakistan (n = 5641) and the US (n = 4756) reported a
signiﬁcantly higher prevalence in Pakistan (12.2% vs. 5.0%, p < 0.01).44
It is estimated that around 1 in 5 adults in India aged 18–39 years
have hypertension.49
In the UK Biobank Prospective Cohort Study (see Table 1 for study
details), South Asians had a higher prevalence of hypertension compared to Europeans (41.8% vs. 38.8%, p < 0.001).50 There was signiﬁcant
heterogeneity in the risk associated with elevated systolic blood pressure such that with every 20-mmHg rise, the hazard of future ASCVD increased by 33% (95% CI 21–45) for South Asians and 12% (95% CI 11–13)
for Europeans, p-heterogeneity <0.001.50 Hypertension accounted for
40% of the ASCVD risk among South Asians compared to 34% among
Europeans, p-heterogeneity <0.05.50
3
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Fig. 1. A unique combination of a higher propensity for early-onset diabetes mellitus, high blood pressure, dyslipidemia, and central adiposity with inherited and epigenetic changes are
associated with a higher incidence of ASCVD among South Asians. This risk is not adequately captured by current risk prediction models, leading to the underutilization of prevention strategies. There is a need for prospective cohort studies to understand the relative importance of the risk factors, along with a commitment to allocate dedicated resources. LDL-C; low density
lipoprotein-cholesterol; HDL-C; high density lipoprotein cholesterol; TG; triglycerides; Lp(a); lipoprotein (a); ASCVD; atherosclerotic cardiovascular disease. Created with BioRender.com

1.42 vs. 1.33).50 This higher risk of ASCVD despite lower LDL-C levels
could be because of smaller and more dense LDL particles among
South Asians, which are more atherogenic.59 The number of LDL particles is reﬂected by apolipoprotein B (apoB) concentration – a higher
concentration for the same LDL-C suggests a higher particle concentration. In the INTERHEART study, South Asians were shown to have a
higher concentration of apoB for any level of LDL-C compared with
other races/ethnicities.34
A more recent analysis of participants in India (n = 4244 from the
Cardiometabolic Risk Reduction in South Asia [CARRS] cohort) and the
US (n = 11,778 from NHANES 2009–2012) also reported that despite
lower median LDL-C (105 vs. 112 mg/dL, p < 0.001), median apoB concentration was higher among Indians (95 vs. 87 mg/dL, p < 0.001).60
Several large epidemiological studies directly comparing
HDL-C levels have reported signiﬁcantly lower HDL-C among South
Asians.33,36,50,61 Among both controls and patients with ﬁrst myocardial
infarction in the INTERHEART study, the prevalence of low HDL-C (<40
mg/dL) was the highest at around 80% in South Asia.36
Other studies also support that South Asians may have a higher
prevalence of dysfunctional HDL.62,63 In the Framingham Offspring
cohort study, despite comparable mean HDL-C levels (41 ± 10 vs.
41 ± 11 mg/dL for immigrant Asian Indian [n = 211] and Caucasian
men [n = 1684], respectively), the concentration of large HDL-C subclasses (H3 + H4 + H5) was lower, and those of small HDL-C subclasses
(H1 + H2) higher among immigrant Asian Indian men.62 These large
HDL-C subclasses are thought to be more efﬁcient at reverse cholesterol
transport, and their lower concentration might result in lower

with limited healthcare access, and increased event rate despite similar
glucose control.58
Low-density lipoprotein-cholesterol (LDL-C), high-density lipoproteincholesterol (HDL-C), and triglyceride (TG)
Key point:
• Lipid abnormalities among South Asians are characterized by higher
concentration of small, atherogenic low-density lipoprotein- cholesterol (LDL-C) particles, higher triglycerides (TG), and lower highdensity lipoprotein cholesterol (HDL-C) concentration.
• South Asians may experience ASCVD events at lower LDL-C levels.
• The cardioprotective effects of higher HDL-C levels may be attenuated
in South Asians.

In the INTERHEART study, among patients with ﬁrst MI, the mean
LDL-C concentration among patients enrolled in South Asia compared
to those from outside South Asia was 121.6 ± 36 vs. 136.2 ± 42.4 mg/
dL (p < 0.001), respectively.34 In the UK Biobank Prospective Cohort
Study, South Asians had lower mean LDL-C compared to Europeans
(130.9 ± 31.9 vs. 139.3 ± 33 mg/dL, p < 0.05).50 This could be due to
a higher proportion of South Asian patients on a statin (20.9 vs.
13.1%).50 In this study, there was a stronger association of ASCVD with
high LDL-C (deﬁned as >160 mg/dL) among South Asians compared
to European ethnicity, after adjusting for age, and gender (hazard ratio
4
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Table 2
Studies directly comparing biological risk factors among South Asian and other racial/ethnic groups.
Author/Year

Site

DM and Metabolic Syndrome
Mohan et al.27/
UK
1986
Kalhan et al.28/
US
2001
Yajnik
India &
et al.29/2002
UK
Ikehara
UK
et al.30/2015
Shah
US
et al.31/2016
Patel et al./ 2021 UK

LDL-C, HDL-C, TG
Kulkarni
et al.32/1999
Anand et al.33/
2000
SHARE
Kalhan et al.28/
2001
Karthikeyan
et al.34/ 2009
INTERHEART
Patel et al./ 2021
UK Biobank
Lipoprotein (a)
Anand et al.35/
1998
Joshi
et al.36/2007
INTERHEART
Patel et al.37/
2021
UK Biobank
Body Composition
Yajnik
et al.29/2002
Rana
et al.38/2014
Anand
et al.39/2016

Shah
et al.31/2016

US
Canada

Findings

No DM: South Asian (n = 15); European (n = 29)
DM: South Asian (n = 45); 72 European (n = 72)
Offspring of South Asian immigrants (n = 32);
Offspring of European Descent (n = 29)
Newborns in India (n = 157) & UK (n = 67)

Higher basal insulin, and total insulin response among those without and
with DM
South Asians had higher fasting plasma insulin, leptin, and truncal skin fold
thickness
Smaller birth weight, signiﬁcantly higher cord plasma leptin and insulin
concentration after adjusting for birth weight
Steeper increase in fasting plasma glucose and lower pancreatic β cell
reserve in South Asians
South Asians have lower adiponectin and higher resistin level, even after
adjusting for body composition

South Asian (n = 230) & 5749 White (n = 5749) without DM
MASALA cohort (South Asian n = 906); MESA cohort (white n =
2622, Chinese American n = 803, African American n = 1893,
Latino n = 1496)
South Asian (n = 8124) & Europeans (n = 449,349) with no
ASCVD at enrollment

Signiﬁcantly higher prevalence of denser LDL-C particles despite the lower
total concentration of LDL-C in South Asians vs. white
South Asian (n = 342), European (n = 326) and Chinese (n = 317) Signiﬁcantly higher total cholesterol, LDL-C, and lower HDL-C among South
Ethnicity
Asian vs. European

32 offspring of South Asian immigrants; 29 of European Descent
(age group 18–30 years)
Asian
Cases with ﬁrst episode of myocardial infarction (n = 5731) and
countries Controls (n = 6549)
UK

South Asian (n = 8124) & Europeans (n = 449,349) with no
ASCVD at enrollment

USA
Canada

Study 1:South Asian (n = 141) & white (US, n = 138)
Study 2:South Asian (n = 255) & white (US, n = 246)
Study 3:South Asian (n = 31) & white (Canada, n = 20)
Patients with ﬁrst episode of myocardial infarction; South Asian (n
= 1732) & other countries (n = 10,728)

South
Asia &
other
UK

India &
UK
Canada
Canada

US

Prevalence of DM is signiﬁcantly higher in South Asia (19.5% vs. 5.3%)
despite younger age (53.5 vs. 57.0 years)

South Asian (n = 39) & white (n = 39); age & gender matched

US

Patel et al./ 2021 UK
UK Biobank
Inﬂammation
Anand et al.33/
2000
SHARE
Chamber et al.40
/2001
Chandalia
et al.41/ 2003
Anand et al.42/
2004
Miller
et al.43/2009
Wandsworth
Heart and Stroke
Study
Patel et al./ 2021
UK Biobank

Participants

South Asians (n = 8124) & Europeans (n = 449,349) with no
ASCVD at enrollment

Newborns in South Asia (n = 157) & UK (n = 67)
Meta-analysis of 50 studies (n = 5,805,313) comparing South
Asian vs. white
South Asian (n = 401) and white (n = 389) newborns

MASALA cohort (South Asian n = 906); MESA cohort (White =
2622, Chinese American = 803, African American = 1893, Latino
= 1496)
South Asian (n = 8124) & Europeans (n = 449,349) with no
ASCVD at enrollment

Signiﬁcantly higher Total Cholesterol: LDL-C ratio and TH levels
Compared to non-Asian regions, South Asian cases had signiﬁcantly lower
LDL-C (125.2 vs 136.2 mg/dL), lower HDL-C (32.5 vs. 40.8 mg/dL) and
comparable TG (163.3 vs. 164.0 mg/dL)
South Asians had lower median LDL-C (130.9 vs. 139.3 mg/dL), lower HDL-C
(49 vs 56.5 mg/dL), higher TG (148.7 vs. 131.2 mg/dL)

Higher median Lp(a) concentration among South Asians in all 3 studies
after age- & gender-adjustment
Higher prevalence of elevated apolipoprotein B100/apolipoprotein A-1 ratio
in both cases (61.5% vs. 48.3%) and controls (43.8% vs. 31.8%) among South
Asians vs. other countries
Median Lp(a) signiﬁcantly higher among South Asians (31.2 vs. 18.5 mg/dL)

Preserved skin fold thickness despite lower body weight, small head and
abdominal circumference
South Asians have higher body fat percentage despite similar BMI.
South Asian women have signiﬁcantly higher waist-hip ratio
South Asian newborns had signiﬁcantly lower birthweight but greater
skinfold thickness and waist circumference.
South Asian ethnicity independent risk factor, along with maternal body fat
and glucose
South Asians have higher visceral fat, and intermuscular fat; lower lean
mass, Lower BMI, body weight and waist circumference than all racial
subgroups except Chinese Americans
Despite comparable BMI (27.2 vs. 27.3 kg/m2), higher waist-hip ratio
among South Asian (9.00 vs. 8.68)

Canada

South Asian (n = 342), European (n = 326) & Chinese (n = 317)

UK

Healthy South Asian (n = 518) & 507 white (n = 507) adults aged Signiﬁcantly higher CRP among South Asian
35–60 years
South Asian (n = 82) & 55 white (n = 55) healthy males
Signiﬁcantly higher hsCRP even after adjusting for total fat and waist
circumference.
South Asian (n = 323), Aboriginal (n = 299), European (n = 322) Higher mean CRP and white blood cell count, even after adjusting for
and Chinese (n = 306)
adiposity, weight and glucose metabolism
South Asian (n = 63), white (n = 61) & Black (n = 68)
Signiﬁcantly higher serum endotoxin level & hsCRP in South Asians

USA
Canada
UK

UK

South Asian (n = 8124) & Europeans (n = 449,349) with no
ASCVD at enrollment

Signiﬁcantly higher homocysteine, plasminogen activator inhibitor-1 and
similar ﬁbrinogen in South Asians vs. Europeans

Signiﬁcantly higher median CRP among South Asian (1.6 [95% CI 0.8, 3.3] vs.
1.3 [95% CI 0.7,2.7] mg/L)

UK; United Kingdom; SHARE: Study of Health Assessment and Risk in Ethnic groups; CRP: C-reactive protein; MASALA: Mediators of Atherosclerosis in South Asians Living in America;
CRP: C-reactive protein; hs: high sensitivity; ASCVD: atherosclerotic cardiovascular disease; BMI: body mass index; Lp(a): lipoprotein(a); DM: Diabetes Mellitus; LDL-C: low density
+lipoprotein-cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein-cholesterol.
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cardio-protection despite a comparable overall HDL-C level.64 Several
studies report higher TG concentration among South Asians vs. other
races/ethnicities, both among healthy participants and those with
CVD.34,65

for a signiﬁcantly higher attributable fraction among South Asians (59%
vs. 25%).50
Dietary risk factors

Lipoprotein(a)[Lp(a)]

Key points
• South Asian dietary practices vary widely within the population, depending on religion, culture, and degree of acculturation.
• There is a mix of cardioprotective (higher odds of vegetarianism, use
of spices, and fasting) and harmful practices (excess salt and simple
carbohydrate consumption) among South Asians.
• Higher consumption of salt is associated with an increased risk of hypertension and future ASCVD among South Asians.

Key point:
• After Blacks, South Asians have the highest Lp(a) levels among all
races/ethnicities and a higher attributable risk for ASCVD.
• Lp(a) levels are genetically determined and help predict risk independent of other lipid abnormalities.

An elevated level of Lp(a) is associated with an increased risk of future CVD events, independent of other risk factors.37,66–69 Serum Lp
(a) levels are genetically determined, and Blacks have the highest concentration followed by South Asians.70
In the INTERHEART study, a higher Lp(a) level was associated with a
higher risk of MI, independent of lipoprotein isoform size.71 While the Lp
(a) concentration was highest among Blacks, the strength of association
of Lp(a) >50 mg/dL with ﬁrst MI was strongest among South Asians with
an odds ratio of 2.14 vs. 1.48 for the entire population after adjusting for
age, gender and apoA and apoB.71 In the UK Biobank study, median Lp
(a) concentration among the Black, South Asian, and White population
was 75, 31, and 19 nmol/L, respectively.37 But the hazard ratios per 50
nmol/L increase were similar (1.07, 1.10, and 1.11, respectively).37 The
different effect sizes in the above two studies could be due to different
baseline characteristics, study design, and event rates.
Current primary prevention guidelines in the US recognize elevated
Lp(a) as a risk-enhancing factor for clinical decision-making but recommend a single threshold for all racial/ethnic groups to identify patients
at high risk of ASCVD (≥50 mg/dL or ≥ 125 nmol/L).5 This topic is discussed in detail in a recent review.70

A large proportion of South Asians (mainly Indians) are vegetarian.
The potential cardioprotective effects of a vegetarian diet may be offset
by increased consumption of saturated fats (such as ghee) and lower
consumption of fresh fruits.58 A recent study used the Alternative
Healthy Eating Index (higher score associated with better eating habits,
lower chronic disease risk) score to compare the diet among participants
in MESA and MASALA cohorts.77,78 South Asians had a higher diet quality
compared with Blacks, Whites, and Hispanics.77 In the UK Biobank Prospective Cohort Study, an unhealthy diet was ascertained based on the
frequency of consumption of the following 7 categories of food: fruits,
vegetables, whole grains, ﬁsh, reﬁned grains and starches, processed
meat, and red meat.50 This consumption pattern was computed in a
diet score, with an unhealthy diet deﬁned as a score ≤ 3. South Asians
had a lower prevalence of an unhealthy diet compared to Europeans
(27.8% vs. 30.4%).50 These ﬁndings are paradoxical given the higher
risk of metabolic diseases among South Asians vs. other races/ethnicities.
Among South Asians in the INTERHEART study, 20% of patients with ﬁrst
MI consume fruits and vegetables >1/d, compared to 38.3% of controls.36
In other parts of the world, this was 26.5% and 45.2%.36 South Asians have
widely different dietary proﬁles and a single measure to assess diet quality will unlikely reﬂect this heterogeneity.79,80
Another CVD risk factor in the South Asian diet is high salt consumption. A systematic review on salt consumption in South Asian countries
reported that mean salt intake is ∼10 g/d, twice the recommended
intake by the World Health Organization (<5 g/day).81

Body composition
Key points
• South Asians accrue CVD risk at lower BMI compared to White individuals.
• Low lean mass and high visceral fat as reﬂected in central adiposity are
better markers of CVD risk than BMI alone.

Impaired kidney function
Key points
• There is a higher prevalence of proteinuria despite a similar estimated
glomerular ﬁltration rate (eGFR) in South Asians compared to White.
• South Asians have a faster decline in eGFR.

In a study of 289 South Asians and 301 Europeans selected randomly
from 4 regions in Canada, a BMI of 21 kg/m2 among South Asians had a
similar association with elevated fasting plasma glucose as a BMI of 30
kg/m2 among Europeans.72 Similarly, in a multi-ethnic study among
1,333,816 White and 75,956 South Asians in a primary care cohort in
England, a BMI cut-off of 23.9 kg/m2 for South Asians was equivalent
to 30 kg/m2 for white for age- and gender-adjusted incidence of DM
over 6.5 years of follow-up.73 This higher risk of DM despite lower
BMI is due to more visceral fat, and lower lean mass which cannot be
distinguished by body weight alone.31,74
Central adiposity is associated with increased production of proinﬂammatory cytokines such as adiponectin which drive insulin resistance and accelerate atherosclerosis.75 Central adiposity is measured
by waist-hip ratio and is not adequately reﬂected in BMI.76 In the UK
Biobank Prospective Cohort Study, South Asians, and Europeans had
comparable mean BMI (27.2 ± 4.4 kg/m2 vs. 27.3 ± 4.8 kg/m2), but
the mean waist-hip ratio was signiﬁcantly higher among South Asians
(9.00 ± 0.85 vs. 8.68 ± 0.89).50 Central adiposity was associated with
a higher risk of future ASCVD in both races/ ethnicities, but it accounted

Chronic kidney disease (CKD) is an independent risk factor for
ASCVD.82 Some regions of South Asia such as Pakistan have one of the
highest age-standardized disability-adjusted life years lost globally to
impaired kidney function. Besides aging, DM, and hypertension, there
are several other novel risk factors such as heavy metal exposure and
pesticide use contributing to a high incidence of CKD, especially in agricultural communities.83
In the UK Biobank study, the prevalence of CKD (deﬁned as
eGFRcystatin < 60 mL/min/1.73 m2) was 7.7% and 4.2% for South Asians
and Europeans, respectively. This study did not include albuminuria in
the assessment of CKD.50 CKD was associated with an increased risk of
incident CVD in both populations (1.57 vs 1.86).50 Another study from
Canada reported South Asians might have a faster rate of CKD progressive compared to Whites (median rate of eGFRcreatinine decline −3.56 vs.
−2.11 mL/min/1.73 m2.84
6
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a stronger association with ASCVD events among South Asians compared to other races/ethnicities.

Albuminuria is a marker of microvascular dysfunction and is associated with worse CVD outcomes, independent of eGFR.85 There is a
higher prevalence of albuminuria among South Asian participants
with CKD compared to other ethnicities despite similar duration and
control of DM.86–88 In a prospective cohort study of Asian Indians recruited in 1988–1991 in Southhall, the United Kingdom, albuminuria,
and not eGFRcreatinine were signiﬁcantly associated with incident CVD
over 22 years of follow-up.89 In the United Kingdom Asian Diabetes
Study, the prevalence of microalbuminuria among South Asians (n =
311) and Europeans (n = 241) was 31% and 20%, respectively, despite
the shorter median duration of DM (6 vs. 8 years) and younger median
age (61 vs. 66 years) among South Asians.86 Despite increased albuminuria, a signiﬁcantly lower proportion of South Asians were on an
Angiotensin-converting enzyme inhibitor/ Angiotensin receptor
blocker (29% vs. 55%).86

PSS is associated with increased CVD morbidity and mortality.94 In a
survey of 4281 adults in England, the prevalence of common mental disorders was higher among immigrants from Bangladesh, India, and
Pakistan compared to White.95 In the South Asian cohort of the
INTERHEART study, the prevalence of stress or depression among patients with ﬁrst MI and controls was 86.0% and 82.6%, respectively.36
The prevalence was similar to other countries (84.2% and 82.0%, respectively). There was a stronger association between stress and depression
among South Asians compared to other countries (unadjusted odds
ratio 2.62 vs. 1.83).36 In the UK Biobank study, South Asians had a higher
prevalence of PSS compared to Europeans (51.7% vs. 43.6%, p < 0.001).50
This PSS had an independent association with increased risk of ASCVD
in both populations.50

Air pollution

Social determinants of health

Key points
• South Asians are exposed to a higher level of ambient and indoor air
pollution from an early age.
• South Asia has one of the highest proportional mortality rates due to
air pollution.

Key Point
• Lower household income and lack of health insurance more common
among immigrant South Asians.

According to GBD 2019, air pollution ranked 4th in the list of modiﬁable risk factors associated with CVD deaths globally.1 South Asia has
one of the highest median concentrations of PM2.5 and agestandardized disability-adjusted life years attributable to particulate
ambient air pollution.1 In India, 1.67 million deaths (95% CI 1.42–1.92)
were attributable to air pollution in 2019, this accounted for 17.8% of
total deaths and 11.5% of total disability-adjusted life years lost in
2019.90 There are several mechanisms by which pollution is associated
with an increased risk of CVD, such as increased inﬂammation, autonomic dysfunction, and endocrine disruption.91 The attributable risk of
increased air pollution in early life to future ASCVD is unknown.92

Social determinants of health have 5 components: economic stability, health care access and quality, social and community context, neighborhood, and built environment, and education access and quality.
These determinants affect a wide range of health outcomes.96 In recent
studies from the MASALA cohort, a better social network was associated
with higher physical activity (PA) and higher odds of ideal cardiovascular health.97 In the same cohort, another study reported a signiﬁcant association between lower income and less education in pre-DM and
DM.98
In the UK Biobank study, the mean Townsend Deprivation Score (a
more positive score that reﬂects higher social deprivation) was signiﬁcantly higher for South Asians vs Europeans.50 Within the South Asian
community, the distribution of social determinants, such as median
household income and education varies widely.11 This knowledge
may help guide targeted population-based interventions in areas with
a higher representation of a particular ethnicity.

Tobacco use
Key points
• In South Asia, besides smoking, tobacco is consumed in various other
forms which may be more predominant.
• Epidemiological studies using questionnaires not standardized for the
South Asian population underestimate the prevalence of tobacco consumption.

Low PA
Key points
• South Asians are less physically active compared to other races/ethnicities.
• There is a signiﬁcant association between low PA with increased
ASCVD in South Asians.

Besides smoking, South Asians consume tobacco in other forms such
as gutka, paan, and supari. A study compared the prevalence of tobacco
consumption among 219 South Asians living in the US using standard
questionnaires routinely employed in surveillance with additional
questions speciﬁcally on these alternate tobacco products.93 The prevalence using standard questionnaires compared to additional questionnaires was 17.2% and 34.7%, respectively. The majority of the
participants who consumed these smokeless forms of tobacco did not
endorse consuming tobacco on the standard questionnaire.93 Using
only smoking as an indicator for tobacco consumption, therefore, vastly
underestimates the prevalence.

South Asians are less physically active v. other races/
ethnicities.36,99,100 For example, in the London Life Sciences Prospective
Population (LOLIPOP) study, mean PA levels with actigraphy were 31%
lower among South Asians (n = 500) compared to Europeans (n =
183).100 The authors found a signiﬁcant inverse correlation of PA with
insulin resistance and fasting plasma glucose after adjusting for age
and gender.100 In the INTERHEART study, among those with MI, the
prevalence of moderate or high-intensity exercise was 4.6% vs. 15.8%
for South Asia compared to other countries, respectively.36 In the UK
Biobank study, South Asians had a higher prevalence of a sedentary lifestyle compared to Europeans (16.8% vs. 12.2%, respectively) with a signiﬁcant association with ASCVD (hazard ratio 1.38 vs. 1.32,
respectively).50

Psychosocial stress (PSS)
Key points
• There is a high prevalence of PSS among South Asians as well as ﬁrstgeneration immigrants.
• This PSS is associated with social determinants of health and may have
7
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Genetic and epigenetic inﬂuence among South Asians

Table 3
Prevention guidelines and their position on South Asian race as a risk enhancer.

Key points
• Data from large genome-wide association studies have identiﬁed several potential loci that are associated with incident ASCVD among
South Asians.
• Along with inherited changes, there might be unique epigenetic
changes due to environmental inﬂuences which can help explain
the residual CVD risk in South Asians.

Guidelines

Position

American College of Cardiology/
American Heart Association
20195

In asymptomatic adults aged 40–75 years of
age and 10-year ASCVD risk score 5- <20%,
consider South Asian race as a risk-enhancing
clinic factor for statin initiation
Multiply risk assessed by QRISK-3 ® score by
1.3 for Indians and Bangladeshis, 1.7 for
Pakistanis
Testing for prediabetes and/or DM in
asymptomatic people should be considered
in adults of any age with overweight or
obesity (body mass index ≥25 kg/m2 or ≥ 23
kg/m2 in Asian Americans) and who have
one or more additional risk factors for DM
(Asian American as high-risk race/ethnicity

European Society of Cardiology
2021105
American Diabetes Association
2022106

In a meta-analysis of 4 large genome-wide association studies comprising 15,420 cases with coronary artery disease (CAD, around 45%
South Asians) and 15,062 controls, there was little evidence of
ancestry-speciﬁc associations, and replication in an independent patient
population identiﬁed 5 new loci that were implicated (LIPA on 10q23,
PDGFD on 11q22, ADAMTS7-MORF4L1 on 15q25, a gene-rich locus on
7q22 and KIAA1462 on 10p11).101
Monocytes and resident macrophages play an important role in cardiac remodeling.102 There is increasing evidence that there might be
single nucleotide polymorphism at genes linked to chemokine receptors
CCR2, CCR5, and CX3CR1A among South Asians. A recent study found 6
variants in CX3CR1A unique to the Pakistani population enrolled in the
Pakistan Risk of Myocardial Infarction Study (PROMIS) cohort that was
associated with DM and MI.103
Wang et al.104 developed a genome-wide polygenic risk score to
identify South Asian adults at high risk of CAD. The authors used
whole-genome sequencing in 1522 South Asians from a populationbased study in India to derive a polygenic risk score that predicted
CAD in 2 separate databases of South Asians - the UK Biobank (n =
7244) study in the UK, and the BRAVE study in Bangladesh (n = 491).
The authors posit that this score can be calculated at the time of birth
and predict CAD risk in middle age.104 The real-world use and costeffectiveness of such genetic risk scores remains to be explored.

European Society of Cardiology, American College of Cardiology, American Heart
Association.

A more recent study compared any detectable CAC in South Asians
enrolled in the MASALA cohort with 4 other races/ethnicities enrolled
in the MESA cohort.107 Among men, age-adjusted crude CAC prevalence
was similar in South Asians compared to Whites (67.9% vs. 68.8%,
p > 0.05.107 Among women, age-adjusted crude CAC prevalence was
lower in South Asians compared to Whites (36.8% vs. 42.6%, p < 0.05),
but South Asian women ≥70 years had a higher prevalence than most
other races/ethnicities107 In another study reporting longitudinal
change after 5 years in any detectable CAC using same cohorts, the
rate of progression of CAC was also similar among South Asian men
and White men (fold change 1.06, 95% CI 0.82–1.36, reference South
Asian).112
In a study among 543 South Asians and 420 Caucasian patients in the
UK with stable chest pain undergoing CT angiography, there was no difference in minimal luminal diameter (2.23 ± 0.97 vs. 2.32 ± 1.02 mm,
p > 0.05), area stenosis (26.24% vs. 27.43%, p > 0.05) or proportion of
one- (9.76% vs. 10.71%), two- (4.05% vs. 2.38%) or three- (1.29% vs.
1.09%) vessel CAD after adjustment for baseline CVD risk factors.113
There was no difference in plaque burden, but the non-calciﬁed plaque
burden (higher burden reﬂects vulnerable plaque) was higher among
South Asians (90.4% vs. 81.0%, p < 0.001).113 A study compared aggregate plaque volume in proximal left anterior descending artery among
age-, gender-, and BMI-matched South Asians, Southeast or East
Asians, and Caucasians (n = 50 for each).114 The study reported the
highest plaque burden among South Asians (44.5 ± 8.4 vs. 37.5 ±
6.5% vs. 39.5 ± 6.4%, p < 0.001, respectively). South Asian race was independently associated with higher plaque volume after adjusting for
traditional CVD risk factors.114
A study among 100 South Asians and 100 European aged 40–70
years with no known CVD or DM reported similar age-adjusted mean
carotid intima thickness (cIMT, 0.64 ± 0.16 vs. 0.65 ± 0.12 mm, p =
0.64).115 Among those 40–50 years of age, the odds of having carotid
plaques were higher among South Asians (odds ratio 2.63, 95% CI
1.16–5.93).115 Another cross-sectional study among 130 South Asians
aged 35–65 years reported around 31% of participants had subclinical
atherosclerosis (cIMT ≥0.8 mm). This increased cIMT was associated
with underlying metabolic syndrome and dysfunctional HDL-C.116

Identifying increased risk
Current risk prediction models
Pooled Cohort Equations underestimate the 10-year risk of ASCVD
among South Asians.5 In the UK Biobank study, the 10-year Pooled Cohort Equation risk score was 4.8% (95% CI 2.1–10.6) and 6.0% (95% CI
2.6–12.0, p < 0.001), for South Asians and Europeans, respectively.50
Over a median follow-up of 11 years, the ASCVD rate was 6.8% vs. 4.4%
(hazard ratio [HR] 2.03, 95% CI 1.86–2.22, p < 0.001). This >2-fold increase in risk was not captured by the risk score.50 A similar Cardiovascular Risk Score (QRISK-3 ®) is validated for the European population
and the European Society of Cardiology recommends multiplying this
score by 1.3 for Indians and Bangladeshis, and 1.7 for Pakistanis for adequate risk assessment (Table 3).105
Detection of subclinical atherosclerosis
Overall, studies comparing coronary artery calcium (CAC) levels
among South Asians and Whites have reported variable results.107–111
This variability could be due to differences in baseline characteristics
such as age, DM, and lack of adequate matching. A study compared
CAC levels in 101 South Asians and 101 Caucasians in the UK who had
no known CAD or CKD.108 The participants had comparable age (54.8
vs. 54.7 years), gender distribution (72.3% men), and family history of
premature CAD (36.6% vs. 35.6%).108 Mean CAC scores were higher in
South Asians (156 ± 27.4 vs. 25.4 ± 6.2, p < 0.0001). A signiﬁcantly
higher proportion of South Asians had triple vessel CAD (25.7% vs.
5.9%).108

Mitigating increased risk
The increased risk of premature ASCVD among South Asians is a
global problem. Current country-speciﬁc policies do not adequately address the ongoing rapid transition in disease epidemiology from communicable to non-communicable diseases such as CVD. Some of the
proposed interventions that can be integrated into existing health infrastructure include health education aimed at primary prevention, annual
risk assessment for hypertension and DM starting at an early age, and a
8
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Non-pharmacological management

coordinated system for escalation of care to decrease the mortality
burden.117 There are several community-level ASCVD programs with a
focus on using a holistic approach to promote health among South
Asians living in the US.118
The House Energy and Commerce Committee in the US recently
passed the South Asian Heart Health Awareness and Research Act of
2021.119 This bill is aimed to establish programs that support heart disease research among communities disproportionately affected by heart
diseases, such as South Asians in the US. The bill, if passed by the Senate
and signed into law, will help accelerate the understanding of underlying mechanisms and plan risk mitigation strategies.

Table 4 outlines studies using non-pharmacological management
among South Asians aimed at primary prevention. In a single-blind,
community-based randomized control trial (RCT) among South Asians
aged ≥30 years and no known CVD at baseline in Canada, digital health
intervention in the form of emails or text messages was sent to improve
diet and physical activity based on participants' self-reported stage of
change.120 The outcome was a change in risk score (consisting age, gender, dietary and PA questions, tobacco exposure, PSS, blood pressure,
waist, and hip circumference, apoA, and apoB, glycated hemoglobin; a

Table 4
Interventions to reduce cardiovascular risk among South Asian ethnicities.
Author/Year Site/Type
Non-Pharmacological
Bhopal
Scotland
et al.
Observational
(21)/2014
PODOSA
US
Kandula
Observational
et al.
(22)/2015
SAHELI
Anand et al. Canada
(23)/2016 Randomized
Ranasinghe Sri Lanka
Randomized
et al.
(24)/2021
SL-DARTS

Pharmacological
Deedwania US & Canada
Randomized
et al.
(25)/
2007
IRIS trial
Gupta et al. Canada
Observational
(26)/
2009
Madan
et al.
(27)/
2012
INFINITY
trial
Brunner
et al.
(28)/2013
Agrawal
et al.
(29)/2018
Jafar et al.
(30)/
2020
COBRA-BPS
study

Docherty
et al. (31)
/2022
DAPA-HF

Canada
randomized

Subjects

Intervention

Findings

1319 Men & Women of Indian and Pakistani
origin, ≥35 years with increased waist circumference and impaired glucose tolerance

15 vs. 4 visits by a dietician over 3 years

Adjusted mean difference in body
weight − 1.64 kg (95% CI -2.83 to
−0.44) over 3 years

63 South Asian immigrants with age 50 ± 8
years

6 interactive group classes focused on increasing
physical activity, healthful diet, weight, & stress
management. Follow-up telephone support calls

Weight loss of 1.5 kg & sex adjusted
decrease in glycated hemoglobin by
0.43% in intervention group at 6 months

343 South Asian men & women aged ≥30
years with no known CVD

Email/ texts focused on improving diet & physical
activity tailored to the participant's self-reported
stage of change vs. control
Aerobic training (n = 28), resistance training (n =
28) and control group (n = 30), training 2/week
for 12 weeks
Outcome: change in glycated hemoglobin at 12
weeks

No difference in myocardial infarction
risk score at 1 year

740 adult patients

Rosuvastatin 10 or 20 mg
Atorvastatin 10 or 20 mg

Both statins & doses well tolerated &
effective in decreasing LDL-C levels

Atorvastatin arm
South Asian n = 48 & White n = 75
Simvastatin arm
South Asian n = 26 & White n = 41
64 SA patients with CAD/ DM & LDL-C ≥ 77
mg/dL despite statin use for ≥4 weeks

Atorvastatin & Simvastatin (median dose 20 mg/d)
for mean 44 and 7 months, respectively

Similar decrease in LDL-C & increase in
HDL-c in both atorvastatin & simvastatin
group

Arm 1: adding ezetimibe 10 mg to current statin
dose
Arm 2: doubling statin dose

Addition of ezetimibe associated with
higher odds of LDL-C reduction to target
levels at 6 & 12 weeks with lower
adverse effects

aHR for mortality 0.69 (95% CI
0.55–0.86) in SA vs. 0.65 (95% CI
0.63–0.67) in White
Both doses equally efﬁcacious at LDL-C
reduction at 3 and 6 months, possible
higher risk of myalgia with higher dose
Greater reduction in systolic blood
pressure (9.0 vs. 3.9 mmHg) reduced
all-cause mortality (2.9% vs. 4.3%) in
intervention group

86 sedentary adults aged 35–65 years with
DM

Canada
observational

New DM; 143,630 White; 9529 South Asian

Statins were prescribed to 27% white; 25% South
Asian

India
Randomized

240 patients with LDL-C ≥ 100 mg/dL and
ASCVD

Atorvastatin 40 mg vs. atorvastatin 80 mg,
outcome:

Rural districts in
Bangladesh,
Pakistan & Sri
Lanka
Randomized

2645 adults aged ≥40 years with
hypertension

Multinational
Randomized

Intervention: home visits by trained government
community healthcare workers with 5
components, including blood pressure monitoring
& referral
Usual care: home visits by existing services from
maternal & childcare only
Duration 24 months
Heart failure with reduced ejection fraction; Dapagliﬂozin vs. placebo with background goal
Out of total 4744, 237 (5%) enrolled in South directed medical therapy
Asia

Change in glycated hemoglobin at 12
weeks
Aerobic 8.1 to 7.4%
Resistance 7.6 to 7.0%
Control 8.7 to 8.2%
No statistically signiﬁcant difference in
change in glycated hemoglobin in
aerobic or resistance group vs. control

Reduced risk of worsening HF or CV
death but attenuated and statistically
insigniﬁcant

aHR: adjusted hazard ratio; ACM: all-cause mortality; SA: South Asians; SAHELI: South Asian Lifestyle Intervention; IRIS; Investigation of Rosuvastatin in South Asians; COBRA-BPS: Control
of Blood Pressure and Risk Attenuation- Bangladesh, Pakistan & Sri Lanka; DAPA-HF; Dapagliﬂozin in Patients With Heart Failure and Reduced Ejection Fraction; PODOSA: The Prevention
of Diabetes and Obesity in South Asians; SL-DART: Sri Lanka Diabetes Aerobic and Resistance Training; DAPA-HF: Dapagliﬂozin and Prevention of Adverse Outcomes in Heart Failure;
Hba1c: glycated hemoglobin.
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higher score predicts a higher risk).121 After 1 year, there was no change
in the risk score in the intervention or control group (13.3 to 12.3 in intervention group [n = 169] vs. 13.3 to 12.6 in control group [n = 174],
risk difference − 0.27, 95% CI -1.12, 0.58, p > 0.05.120 Similar studies
using digital health intervention in other populations have shown
mixed results.122–124 There could be a short-term reduction in CVD
risk factors such as body weight, average blood sugar, and blood pressure but this risk reduction may not be sustained long term.
To address the high prevalence of hypertension, several populationlevel interventions to reduce median household salt consumption have
been evaluated. A recent review discusses these strategies in detail.81
Any non-pharmacological intervention to reduce CVD risk in South
Asians has to incorporate heterogeneity such as dietary and cultural
practices.

ﬁndings- the risk of myopathy and potential dose reduction for comparable beneﬁt in South Asians- remains unknown.

Pharmacological management

The opinions expressed reﬂect those of the author and not necessarily those of the Department of Veterans Affairs or the US government.

Conclusion
The incidence of ASCVD is increasing rapidly in the South Asian ethnicity and this risk is underestimated by current risk calculators. Currently, South Asian ethnicity is considered a risk-enhancing factor
when ASCVD risk is borderline or intermediate. Given the cumulative
evidence discussed above, South Asian ethnicity is a risk equivalent
rather than a risk enhancer alone. This is a concern that should be addressed in future ASCVD prevention guidelines.
Declaration of Competing Interest

In an observational study among 9259 South Asian patients who
were ﬁrst diagnosed with DM between 1993 and 2006, statins were
prescribed to 25% (mean age 56.1 years, 47.9% women, 14.6% patients
overall had a history of MI).125 Data on statin therapy for primary prevention was not reported separately.125 There was a signiﬁcant reduction in the risk of all-cause mortality (adjusted HR 0.69, 95% CI
0.55–0.86) and the composite outcome of all-cause mortality, MI, and
stroke (adjusted HR 0.83, 95% CI 0.70–0.99, p = 0.04). This risk reduction was similar to Chinese and White patients in this study.125 Statins
were well tolerated with no reports of increased myalgia or drug discontinuation rates compared to other races/ethnicities.
Despite the proven beneﬁt of statins for primary prevention in highrisk populations, there is a low rate of statin use among South Asians,
even among those with DM. In a multisite study published in 2016
from India, among 8699 patients with DM, only 55.2% were prescribed
a statin.126 Among those <40 years of age, the prescription rate was
only 34.3%.126 In this study, only 58% of patients with high risk
(micro- or macrovascular complications of DM) were prescribed a
statin. Data from primary care centers in the UK from 2006 to 2019 suggest that among those with DM, patients of South Asian ethnicity were ∼
10% less likely to be on a statin compared to European ethnicity, even
after adjusting from baseline cholesterol levels and other ASCVD risk
factors.127 The authors reported that equalizing statin prescription
could potentially prevent an additional 6331 ASCVD events over the
lifetimes among South Asians with DM in the UK.127
A recent study examined the prescription pattern of lipid-lowering
medications from 2008 to 2018 in 83 countries using monthly pharmaceutical sales data.128 This pattern was not adjusted for the age or baseline CVD risk of patients. The study reported that South Asia has one of
the lowest rates of lipid-lowering medication use, both in 2008 and
2018. In 2018, only 1.0% and 0.4% of the population were on a lipidlowering medication in India and Pakistan, respectively (compared to
9.0% in the US). However, it was encouraging to note that there was a
substantial increase in the use from 2008 to 2018 with a compound annual growth rate of 10.4% and 10.5%, in India and Pakistan, respectively
(compared to 2.2% in the US). Statins constituted >90% of these lipidlowering medications in South Asia.128
A study done among 36 White and 35 Asian-Indian subjects in
Singapore studied the pharmacokinetics of statin metabolism and reported that with a 40 mg dose of rosuvastatin, maximum plasma concentration, and cumulative exposure were > 2 times among AsianIndians compared to White.129 In an observational study of 202 patients
on atorvastatin or rosuvastatin for 12 years, statin-associated myopathy
was deﬁned using clinical symptoms and creatine kinase >5 times the
upper limit of normal.130 The prevalence was 18%. The authors reported
a higher frequency of CYP3A5 polymorphism in these patients. A metaanalysis of 8 observational studies with 1614 participants reported that
CYP3A5*3 polymorphism was associated with myopathy with an odds
ratio of 1.30 (95% CI 0.96, 1.75).131 The clinical relevance of such
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